Gia Landry, MD
Gastroenterology · Baton Rouge, LANPI 1053467365
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $364,492 of the $511,026 with a category attached, or 71.3%. Gilead accounts for 74.9% of it on its own, with 24 other manufacturers making up the rest. 2025 is the largest year on record at $161,718, 6.4 times the $25,185 reported in 2019. Among gastroenterology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 633 payments — averaging $807.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$383K
- Madrigal Pharmaceuticals$111K
- Fujifilm Healthcare Americas Corporation$8K
- Ipsen Biopharmaceuticals, Inc$7K
- AbbVie$524
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$369
- plus $2K from 19 others
What the payments were for
- Consulting fees$58,10011%
- Speaking & faculty fees$364,49271%
- Travel & lodging$74,20915%
- Food & beverage$14,1733%
- Education$520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 389 | $382,874 |
| Madrigal Pharmaceuticals | 101 | $111,125 |
| Fujifilm Healthcare Americas Corporation | 7 | $7,859 |
| Ipsen Biopharmaceuticals, Inc | 11 | $6,615 |
| AbbVie | 24 | $524 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 20 | $369 |
| Intercept Pharmaceuticals, Inc. | 16 | $269 |
| Mallinckrodt Hospital Products Inc. | 6 | $216 |
| Ardelyx, Inc. | 12 | $210 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $189 |
| Boston Scientific | 1 | $102 |
| QOL Medical, LLC | 5 | $97 |
| Phathom Pharmaceuticals, Inc. | 6 | $96 |
| Sanofi | 4 | $86 |
| Novo Nordisk | 3 | $83 |
| Eisai Inc. | 2 | $57 |
| Shionogi Inc | 4 | $55 |
| GSK | 1 | $50 |
| Regeneron Healthcare Solutions, Inc. | 1 | $38 |
| Orphalan Inc | 1 | $24 |
| Aimmune Therapeutics, Inc. | 1 | $23 |
| Braintree Laboratories, Inc. | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Pfizer | 1 | $17 |
| Dynavax Technologies Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epclusa$258,460
- REZDIFFRA$109,659
- Livdelzi$64,843
- Vemlidy$25,246
- uTASWako AFP-L3$7,675
- IQIRVO$6,406
- TERLIVAZ$137
- Rinvoq$124
- TheraSphere Y90 Glass Microspheres 10 GBq$102
How this compares
$511,026 in reported general payments places this provider in the 95th percentile of 254 gastroenterology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpclusaSofosbuvir/Velpatasvir | 17 | $404,172 |
| XifaxanRifaximin | 98 | $313,584 |
| Sofosbuvir-VelpatasvirSofosbuvir/Velpatasvir | 16 | $157,333 |
| VemlidyTenofovir Alafenamide | 57 | $81,723 |
| RezdiffraResmetirom | 14 | $55,855 |
| Tacrolimus | 327 | $39,583 |
| Sirolimus | 49 | $21,687 |
| Envarsus XrTacrolimus | 11 | $12,429 |
| Ursodiol | 108 | $11,067 |
| Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf) | 15 | $10,306 |
| LinzessLinaclotide | 15 | $8,213 |
| Mycophenolate Mofetil | 95 | $6,981 |
| Tenofovir Disoproxil Fumarate | 48 | $5,789 |
| Cyclosporine ModifiedCyclosporine, Modified | 41 | $4,603 |
| Lactulose | 100 | $4,067 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa, Vemlidy | $382,874 | $485,89574 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $369 | $313,58498 claims |
| Madrigal PharmaceuticalsRezdiffra | $111,125 | $55,85514 claims |
| AbbVieLinzess | $524 | $8,21315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 254 gastroenterology providers in Louisiana.
Other gastroenterology in Baton Rouge
- Jonathon ChapmanBaton Rouge$998K
- Gregory GaspardBaton Rouge$86K
- Neelima ReddyBaton Rouge$23K
- Ronald LeoBaton Rouge$9K
- Conar FittonKenner$955K
- Charles MonierThibodaux$448K
- Nathaniel RanneyCovington$392K
- Georges CatinisMetairie$346K
- Humberto AguilarShreveport$313K
- Sarah GloverNew Orleans$274K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.